Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CYTOMEL | King Pharmaceuticals | N-010379 RX | 1982-01-01 | 3 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
adthyza | unapproved drug other | 2023-02-23 |
adthyza thyroid | unapproved drug other | 2023-12-08 |
cytomel | New Drug Application | 2019-07-24 |
liothyronine sodium | ANDA | 2024-10-16 |
np thyroid | unapproved drug other | 2021-05-11 |
np thyroid 120 | unapproved drug other | 2024-10-15 |
np thyroid 15 | unapproved drug other | 2024-10-29 |
np thyroid 30 | unapproved drug other | 2024-10-29 |
np thyroid 60 | unapproved drug other | 2024-10-30 |
np thyroid 90 | unapproved drug other | 2024-11-13 |
Drug common name | Liothyronine |
INN | liothyronine |
Description | 3,3',5-triiodo-L-thyronine is an iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. It has a role as a thyroid hormone, a human metabolite and a mouse metabolite. It is an iodophenol, a 2-halophenol and an iodothyronine. It is a conjugate acid of a 3,3',5-triiodo-L-thyroninate. It is a tautomer of a 3,3',5-triiodo-L-thyronine zwitterion. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O |
PDB | — |
CAS-ID | 6893-02-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1544 |
ChEBI ID | 18258 |
PubChem CID | 5920 |
DrugBank | DB00279 |
UNII ID | 06LU7C9H1V (ChemIDplus, GSRS) |